Grail's Potential Turnaround: Seeking FDA Approval For Galleri (NASDAQ:GRAL)
GRAIL, Inc. (GRAL) develops multi-cancer early detection tests using NGS technology, with its Galleri test detecting over 50 cancer types from a blood sample. The company aims to secure FDA approval for Galleri, which could enhance market acceptance and insurance coverage, potentially improving patient outcomes through early detection. GRAL is currently a standalone company after being spun off from Illumina, with a focus on cost-cutting measures and FDA approval to become a sustainable entity.
Related News
GRAIL, Inc. (GRAL) develops multi-cancer early detection tests using NGS technology, with its Galleri test detecting over 50 cancer types from a blood sample. The company aims to secure FDA approval for Galleri, which could enhance market acceptance and insurance coverage, potentially improving patient outcomes through early detection. GRAL is currently a standalone company after being spun off from Illumina, with a focus on cost-cutting measures and FDA approval to become a sustainable entity.